BUG 8C BEA.$DSLEY, LLP. 919 EIGHTEENTH STREET, N.W. SUITE C300 WASHINGTON, D.C. 2000C3-55ro. October 22, 2009
|
|
- Reynold Stewart
- 5 years ago
- Views:
Transcription
1 BUG 8C BEA.$DSLEY, LLP 919 EIGHTEENTH STREET, N.W. SUITE C300 WASHINGTON, D.C. 2000C3-55ro OCT 22?3 '07 W$rrEa's TmmEPjKoxE TE-1-Rp$oxE FAcsnKn.R Dockets Management Branch (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD Re : Citizen Petition Requesting that FDA Not Approve an Abbreviated New Drug Application for Cefixime for Oral Suspension Unless Certain Requirements are Met _ Dear Sir or Madam : On behalf of Lupin Pharmaceuticals, Inc. (`Lupin"), a wholly owned subsidiary of Lupin Limited, which it represents, Buc & Beardsley, LLP hereby submits this Citizen Petition under sections 505(j) and 505(q) of the Federal Food, Drug, and Cosmetic Act ("FDCA" or the "Act") (21 U.S.C. 355(j) and (q)) and 21 C.F.R to request that the Commissioner of Food and Drugs take the following action. 1. Action Requested Lupin requests that the Commissioner not approve any abbreviated new drug application ("ANDA") for cefixime for oral suspension that relies on Suprax (cefixime) for oral suspension as the reference listed drug ("RLD") unless the ANDA meets the same standards for strength, potency, quality, impurities, stability and overage of cefixime active ingredient that Lupin was required to meet in order to obtain approval of its ANDA. 11. Statement of Grounds Lupin markets specialty pharmaceuticals and generic drugs. Among the drugs that Lupin markets is Suprax (cefixime) for oral suspension in 100 mg/5 ml and 200 mg/5 ml strengths. Suprax is an antibiotic indicated for treating urinary tract infections, otitis media, pharyngitis and tonsillitis, acute bronchitis and acute exacerbations of chronic bronchitis and uncomplicated gonorrhea caused by susceptible organisms in adults and children, including infants down to six
2 Page 2 months of age.' Lupin holds ANDAs and for the 100 mg/5 ml and 200 mg/5 ml strengths respectively. No patents are listed for, and no exclusivities apply to, Suprax. The RLD for Lupin's ANDAs was Lederle's formulation of Suprax, which has since been discontinued. The approval process for Lupin's Suprax was complex. Lupin's original ANDA for the 100 mg/5 ml strength was submitted on May 14, There was significant discussion regarding overages during the ANDA review process. Lupin was required to perform additional studies and was ultimately required to reduce the overage that it had originally proposed to match the overage in the reference listed drug. In addition, Lupin was asked to and did provide substantial additional information about impurities in its product, including a comparative analysis to the RLD, and tightened the specifications for several impurities at the request of FDA. Lupin's ANDA was approved with an overage equivalent to, and with specifications similar to, the Lederle Suprax formulation, on February 23, A supplemental application to revise certain specifications and product shelf life was subsequently submitted on August 12, 2008 and approved on April 14, Lupin's ANDA for the 200 mg/5 ml strength was submitted on September 23, Having had previous experience with FDA's views on overages and specifications, Lupin submitted the ANDA with the same percentage overage that had been previously approved in the 100 mg/5 ml strength and with similar specifications. This ANDA was approved on April 10, Lupin recently learned that another sponsor has submitted an ANDA referencing Suprax, and believes that this and future ANDA applicants may be seeking approval of a drug with an overage greater than, and impurity specifications less tight than those for Lupin's products. Because including a greater overage might allow for more degradation and because less tight specifications might allow for use of a simpler and more cost-efficient manufacturing process, Lupin believes approval of such a drug could cause it to suffer significant competitive harm. If an ANDA applicant were to represent that Lupin's product has overages higher than those approved by the FDA, Lupin believes that this representation would not be correct and would point towards an analytical method that is giving an incorrect result. 1. Suprax Prescribing Information, Indication and Usage ; Prescribing Information, Pediatric Use.
3 Page 3 A. Approving an ANDA with an Overage Greater than the Overage in the RLD Would Not Be in Accordance with Law and FDA Policy Pursuant to FDCA 505(j) and 21 C.F.R and , an ANDA applicant generally must demonstrate, among other things, that the strength 2 of its product is identical to that of the RLD. The legal standard incorporates the scientific presumption that if the drug covered by the ANDA has the same strength (and shares other relevant attributes enumerated by the statutory standards), it will have the same safety and efficacy as the RLD, and will be substitutable with the RLD.3 An ANDA for a different strength product than the RLD can only be received by FDA if the applicant submits, and FDA approves, a suitability petition allowing the change. 4 For these reasons, ANDA applicants are generally required to formulate a drug with the intent of providing the exact strength of the reference listed drug, no less and no more.5 In some cases, FDA may permit the use of a small "stability overage," i.e., the addition of active ingredients beyond the labeled concentration to compensate for anticipated loss of the ingredient over time. This approach can be used to extend the shelf life of products, but it is generally discouraged 6 because it may result in patients receiving "super-potent" doses of active ingredient (above the labeled strength)7 and/or drugs with concentrations of degradation impurities that exceed those that would be found if an overage was not used (also posing a potential safety issue depending on the toxicity of the impurities).g In the case of Suprax, FDA told Lupin that its 2. Strength is defined as the concentration of active ingredient in the drug and/or its potency. 21 C.F.R (b)(16) Fed. Reg , (Apr. 28, 1992); Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research ("CDER"), Regarding Docket Nos P-0323/CPI et al., 7 (Oct. 14, 2003), available at http :// c Exhibit-29-vol4.pdf; FDA Orange Book, vii (29th Ed., 2009) C.F.R A product with different strength will not be substitutable with previously approved products C.F.R (a) ; FDA/ICH Guidance for Industry : Q8(R1) Pharmaceutical Development, 5 (Rev. 1, June 2009). 6. FDA/ICH Guidance for Industry : Q8(R1) Pharmaceutical Development, E.g., 10/4/2006 Advisory Committee Regarding Levothyroxine, 20 (Jane Axelrad, Esq., Associate Director for Policy, CDER stating that manufacturers generally target 100% strength (i.e., with no overage) at release because it "eliminates the risk of a patient obtaining a super potent product"), available at http :// FDA has previously determined that a small overage of a specified amount in a cefexime for oral suspension product is safe, and an ANDA applicant is entitled to rely on that previous determination. 8. E.FDA Warning Letter to Medico Labs, Inc. (Apr. 16, 2007) (Regarding the "potential clinical concern" due to the excess degradants that could result from an overage), available at http ://
4 Page 4 principal concern was the excess of degradation impurities that would result from adding a substantial overage. When FDA has approved an RLD with an overage, i.e., found the RLD with the overage to be safe and effective, an ANDA applicant is permitted to include an overage in its product and match the true strength of the RLD. In that case, the ANDA drug would meet the identical strength requirement of the statute and regulations. If, however, the overage exceeds levels in the RLD, the strength of the product would be different than that of the RLD, and would raise questions about safety and substitutability of the product. In apparent recognition of this, FDA has stated that "in general, the only acceptable justification for an overage in the final [ANDA] drug product formulation is the demonstration of the same overage in the RLD."9 FDA approved Lupin's Suprax with an overage which was demonstrated to match the overage in the Lederle RLD. If FDA were to approve an ANDA referencing Suprax that permitted a higher overage, FDA would both be approving a drug of a different strength and contravening the legal requirement that the strength of ANDA and RLD products be that same (i.e., "identical"), as well as its own often stated policies.] In reviewing any ANDA that represents that Lupin's drug has an overage greater than that represented by Lupin (even given the tolerances of analytical variation), Lupin requests that FDA carefully review the analytical method used to obtain such results before concluding that the ANDA applicant is correct. B. Approving an ANDA with an Overage Greater than the Overage in the RLD Would Be Arbitrary and Capricious It is axiomatic that an agency must "treat similar cases in a similar manner unless it can provide a legitimate reason for failing to do so."' 1 "Government is at its most arbitrary when it 9. FDA Office of Generic Drugs, Question-based Review ("QbR") Frequently Asked Questions, 16 (June 4, 2007). See also, e.., FDA Guidance for Industry, Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - Chemistry, Manufacturing, and Controls Documentation, 5 (July 2002). 10. Lupin is aware that the U.S.P. monograph, Cefixime for Oral Suspension, provides a range of % for strength measurements, and that some might argue that this specification should allow upward variation within the range. Such ranges, however, are generally adopted to take account of variability in analytical methods, not to provide a range of different active ingredient concentrations. E.g_, 10/4/2006 Advisory Committee Regarding Levothyroxine, 41 (an upper limit of 110% on levothyroxine potency is primarily intended to accommodate analytical variability in methods that are used to measure strength). 11. Independent Petroleum Ass'n of America v. Babbitt, 92 F.3d 1248, 1258 (D.C. Cir. 1996) ~ National Association of Broadcasters v. FCC, 740 F.2d 1190, 1201 (D.C. Cir. 1984) ; see also Transactive Corp. v. U.S., 91 F.3d 232, 237 (D.C. Cir. 1996) ; Doubleday Broadcasting Co. v. F.C.C., 655 F.2d 417, 423 (D.C. Cir. 1981).
5 Page 5 treats similarly situated people differently."' 2 These general principles of administrative law are as applicable to FDA in the approval context as to any other administrative action. In Bracco v. Shalala,l3 for example, FDA's decision to regulate some contrast agents as drugs and others as devices was challenged. Holding that the plaintiffs were likely to succeed on the merits of their challenge to the regulatory scheme, the court concluded that "[t]he disparate treatment of functionally indistinguishable products is the essence of the meaning of arbitrary and capricious."14 The same principle applies here. The situation that Lupin believes may exist - an ANDA that proposes an overage greater than that in the RLD - is, in all relevant respects, the same situation that Lupin faced when its ANDA was pending. Both situations involve a pending cefixime for oral suspension ANDA in which an overage higher than the overage in the RLD is proposed. When considering Lupin's ANDA, FDA refused to approve the ANDA unless the overage in Lupin's drug was no greater than the overage identified in the RLD. Lupin was therefore required to change its formulation to reduce the overage to obtain an approval. This required Lupin to reformulate and to reduce Suprax's shelf life to ensure that Suprax remains stable over the life of the product. It would be arbitrary and capricious for FDA now to approve a competitor without imposing the same requirement. Lupin recognizes that federal agencies are not precluded from changing their policies in appropriate circumstances. But they "cannot silently depart from previous policies or ignore precedent." 15 In this case, however, Lupin has no reason to think that FDA has changed its policy, or that it would want to do so. FDA's Guidance on Chemistry, Manufacturing, and Controls ("CMC") Information still states that, in general, use of an overage is not appropriate, and FDA's Question-based Review Frequently Asked Questions still provides that; in general, the only acceptable justification for an overage is a demonstration of the same overage in the RLD. Further, FDA's review of an ANDA referencing Suprax provides no reason to change the policy. No patent prevents ANDA applicants from manufacturing in the same way that Lupin does, and the experience of Lupin, and Lederle before it, demonstrates that it is possible to manufacture a cefixime for oral suspension with an overage not more than that in the original Lederle Suprax RLD, while still supporting a commercially reasonable shelf life. There is no reason to believe that another manufacturer willing to devote sufficient resources to its drug 12. Eteison v. Office of Personal Mana e~ ment, 684 F.2d 918, 926 (D.C. Cir. 1982) F. Supp. 20 (D.D.C. 1997). 14. Id. ; see also U.S. v. Diapulse Corp. of America, 748 F.2d 56, 62 (2d Cir. 1985). 15. Committee for Community Access v. FCC, 737 F.2d 74, 77 (D.C. Cir. 1984).
6 Page 6 development could not obtain the same result as manufacturers before it. for another manufacturer makes little sense. 16 Relaxing the standard C. FDA May Not Approve an ANDA for a Drug Without Rigorous Scrutiny of the Impurities in the Drug, Especially as Compared to the Impurities in the RLD FDA cannot approve an ANDA if its CMC "are inadequate to assure and preserve its identity, strength, uali, and puritx."i7 The presence of impurities in an ANDA drug which are different than those found in the RLD, or at a higher concentrations than those found in the RLD, can raise questions about whether this standard is met, and relatedly, the safety of the product. j g The different impurities, or impurities at higher concentrations, generally must be "qualified," (i.e., potential safety issues assessed) prior to ANDA approval using data from existing sources (e.g_, literature), if available, or by conducting studies (e.g_, toxicity studies), if such data are not available. 19 In addition, because concentrations of certain impurities (namely, degradants) can change over time, it is crucial that qualifications, and limits, on impurities take into consideration the drug product's changing composition over its shelf life.2 FDA rigorously applied these standards when it reviewed Lupin's original ANDAs and supplements for Suprax, requiring Lupin to reduce the levels of certain impurities, qualify others with extensive toxicology testing, conduct its impurity evaluations over the entire shelf life proposed for its product, and conduct comparative analyses to the RLD. Any ANDA following Lupin's must be held to the same high standards by the agency, to ensure the quality, purity, and 16. An applicant's inability to make a product that matches the Lupin overage also raises questions about the adequacy of CMCs. Like NDAs, ANDAs are required to have CMCs that are "adequate to ensure... the strength" of the product, and allow it to perform as labeled. FDCA, 505(j)(4) ; Letter from Randall W. Lulter, Ph.D., Acting Associate Commissioner of Policy and Planning Regarding Docket Nos. 2004P-0206/CPI et al., (Feb. 22, 2006), available _at http :// R= c1I. 17. FDCA 505(j)(4)(A) ; 21 C.F.R (a)(1) (emphasis added). 18. See e.g., Letter from Janet Woodcock, M.D., Director, CDER, Regarding FDA 2005-P-0367 (Nov, 17, 2008), available at http :// documentdetail?r= b06cd. 19. FDA Draft Guidance for Industry : ANDAs : Impurities in Drug Products, 5-6 (Rev. 1, Aug. 2005). 20. FDA/ICH Guidance for Industry : Q3B(R2) Impurities in New Drug Products, 5 (Rev. 2, July 2006).
7 Page 7 safety, of the product, and for the agency to fulfill its legal obligation to treat similarly situated products in a similar fashion, as discussed above. 21 To relax the standard to which Lupin's products were held for another generic applicant could result in a commercial disadvantage for Lupin if, as Lupin believes based on its own experiences with manufacturing processes for Suprax and other similar products, such an applicant would be able to use a process that would not require as much control over impurities, and therefore, be more commercially efficient. III. Environmental Impact Petitioner claims a categorical exclusion under 21 C.F.R and 25.31(a). IV. Economic Impact Petitioner will submit economic information upon request of the Commissioner. 21. FDA's Draft Guidance for Industry : ANDAs : Impurities in Drug Products 3-4, provides that, in establishing degradation product acceptance criteria, ANDA should look first to U.S.P. specifications, and, if there are none, to levels observed in the approved human drug product. The U.S.P. monograph, Cefixime for Oral Suspension, contains no impurity specification.
8 Page 8 V. Certification I certify that, to my best knowledge and belief : (a) this petition includes all information and views upon which the petition relies ; (b) this petition includes representative data and/or information known to the petitioner which are unfavorable to the petition ; and (c) I have taken reasonable steps to ensure that any representative data and/or information which are unfavorable to the petition were disclosed to me. I further certify that the information upon which I have based the action requested herein first became known to the party on whose behalf this petition is submitted in the last two months. 22 If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations : Lupin Limited. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition. Respectfully submitted, G Lea.c,d s ~nw G. a :,~- Kate C. Beardsley James A. Boiani Buc & Beardsley, LLP th St., NW Suite 600 Washington, DC Phone : (202) The specific information that became known within the last two months was that another ANDA for a cefixime oral suspension product had been submitted to the agency. This information, and a concern that FDA might relax its application of the standards for approval to cefixime ANDAs, prompted this petition.
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015
DEPARTMENT OF HEALTH & HUMAN SERVICES Silver Spring, MD 20993 ANDA 060851 Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY 10970 Docket No. FDA-2011-P-0081
More informationNAVINTA LLC FEB loa II: 2 2. February 9, 2011
February 9, 2011 NAVINTA LLC 2011 FEB loa II: 2 2 Fax: 609883 1137 Ms. Michelle Bigesby, Division ofdocuments Management, Food and Drug Administration, Department ofhealth and Human Services; 5630 Fishers
More informationthe May 2010 Draft Guidance on Azelaic Acid, and you request that the FDA take the following actions relating to those comments:
(.t ~stltvic's. ~"~Iy"~ DEPARTMENT OF HEALTH &. HUMAN SERVICES JUN 22 2012 Food and Drug Administration Rockvile MD 20857. David L. Rosen Foley & Lardner LLP 3000 K Street, N.W., Suite 500 Washington,
More informationI. BACKGROUND. Docket No. FDA-2009-P Dear Dr. Aikman:
DEPARTMENT OF HEALTH &. HUMAN SERVICES Food and Drug Administration Rockville MD 20857 Mark S. Aikman, Pharm.D. Vice President, Regulatory Affairs and Quality Assurance Osmotica Pharmaceutical Corp. 1205
More informationFEB 28 A 9 :09
InvaGen Pharmaceutic als. Inc. InvaGen Pharmaceuticals, Inc. Te1:631-231-3233 Fax:631-231-4248 4 2 3 7 11 FEB 28 A 9 :09 Division of Dockets Management Food and Drug Administration Department of Health
More informationJanssen T. October 31, 2016
Docket No. FDA-2011-P-0086-0001/CP Janssen Research & Development, LLC. 1125 Trenton-Harbourton Road, P.O. Box 200 Titusville, NJ 08560 Janssen T October 31, 2016 Division of Dockets Management (HF A 305)
More informationD1)-(c790//./0, o 93/ op
ZUCKERMAN SPAEDER 1900 M STREET, NW SUITE 1000 WASHINGTON, DC 20036-5802 202.778.1800 202.822.8106 fax www.zuckerman.com Kate C. Beardsley Partner (202) 778-1866 kbeardsley@zuckerman.com Division of Dockets
More informationJAN MbTten Jurs Chief Executive Officer Pronova BioPharma Norge AS P.O. Box 420 NO-1327 Lysaker NORWAY. Docket No.
DEPARTMENT OF HEALTH &. HUMAN SERVICES Food and Drug Administration Rockville MD 20857 JAN 28 2010 MbTten Jurs Chief Executive Officer Pronova BioPharma Norge AS P.O. Box 420 NO-1327 Lysaker NORWAY Re:
More informationLACHMAN CONSULTANT SERVICES, INC STEWART AVENUE, WESTBURY, NY (516) " FAX (516) $,7,1 OVERNIGHT COURIER 11/16/09
LACHMAN CONSULTANT SERVICES, INC. CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES 1600 STEWART AVENUE, WESTBURY, NY 11590 (516) 222-6222 " FAX (516) 683-18$,7,1 November 16, 2009 OVERNIGHT COURIER
More informationNAVINTA LLC Fax:
AVITA LLC Fax: 609 883 1137! 2011 FEB - 8 A 10: 2q February 7, 2011 VIA OVERIGHT DELIVERY Division of Documents Management Food and Drug Administration Department of Health and Human Services 5630 Fishers
More informationWithdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for
This document is scheduled to be published in the Federal Register on 12/14/2018 and available online at https://federalregister.gov/d/2018-27098, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationUNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION Citizen Petition to: Margaret A. Hamburg, M.D, Commissioner of Food and Drugs Docket No. For Review of Standard of Identity
More informationrj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION
rj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION HAR 1 0 2017 Anthony Maffia Vice President, Regulatory Affairs Sandoz Inc. 1 00 College Road West Princeton, NJ 08540 Dear Mr. Maffia: Re: Docket No. FDA-2016-P-3356
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationInvaGen. FDP..90 fit P(Do47. Citizen petitian
InvaGen Pharmaceuticals, I nt. InvaGen Pharmaceuticals, Inc. Te1:631-231-3233 Fax:631-231-4248 4:91. 6 11. Division of Dockets Management Food and Drug Administration Department of Health and Human Services
More informationOver-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen
Reprinted from FDA s website by EAS Consulting Group, LLC Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Center for Drug Evaluation and Research
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Center for Drug Evaluation and Research DATE: February 16, 2017 TO: FROM: Ganciclovir injection 500mg/250ml (NDA
More informationHogan Lovells. December 11, 2013 BY HAND DELIVERY
Hogan Lovells 13 777 BY HAND DELIVERY Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 Re: CITIZEN PETITION SUPPLEMENT On behalf of AbbVie Inc. ("AbbVie") 1, the undersigned
More informationUNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT Date of docketing: December 1, 2017 NOTICE OF DOCKETING 18-1247 - Amarin Pharma, Inc. v. ITC Appeal from: U.S. International Trade Commission Investigation
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More informationMay 7, Dear Mr. Landa:
Ralph A. Simmons 202 429 6459 rsimmons@steptoe.com 1330 Connecticut Avenue, NW Washington, DC 20036-1795 202 429 3000 main www.steptoe.com May 7, 2013 Michael M. Landa Director, Center for Food Safety
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationjjc Troxyca (Oxycodone Hydrochloride and Naltrexone Hydrochloride) ER capsules (new drug application (NDA) ) TO:
TO: FROM: THROUGH: Troxyca (Oxycodone Hydrochloride and Naltrexone Hydrochloride) ER capsules (new drug application (NDA) 207621) Emily Helms Williams Wi Regulatory Counsel / Office of Regulatory Policy
More informationperpetuate -- and perhaps even intensify -- that controversy. 1 On July 18th, the Fifth Circuit affirmed FDA s longstanding position that
Food & Drug July 29, 2008 Fifth Circuit Rules that FDA May Regulate Compounded Drugs as New Drugs Update on Medical Center Pharmacy v. Mukasey For decades, the pharmacy compounding industry has disputed
More informationListing of Color Additives Exempt from Certification; Synthetic Iron Oxide
This document is scheduled to be published in the Federal Register on 03/20/2015 and available online at http://federalregister.gov/a/2015-06418, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationClass II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA
Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the
More informationNOV
DEPARTMENT OF HEALTH &, HUMAN SERVICES ------------------------------------------ NOV 17 2010 Food and Drug Administration Rockville M D 20857 Mark S. Aikman, Pharm.D. Vice President, Regulatory Affairs
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA UNITED STATES OF AMERICA v. CRIMINAL NO. UCB, INC., Defendant. VIOLATION 21 U.S.C. 331(k), 352(f)(1), and 333(a)(1) (Causing drugs to be
More informationDecember 4, 2017 VIA ELECTRONIC SUBMISSION
VIA ELECTRONIC SUBMISSION December 4, 2017 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Development of a List of pre-dietary Supplement
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments
More informationMartin Shimer Deputy Director, Division of Legal and Regulatory Support Office of Generic Drug Policy
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: November 9, 2017 FROM: Martin Shimer Deputy
More informationTHE WEINBERG GROUP VIA FEDEX. October l, 2009
.. 0 THE WEINBERG GROUP VIA FEDEX October l, 2009 Division of Dockets Management Food and Drug Administration (HFA-305) Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD
More informationBEFORE THE FEDERAL COMMUNICATIONS COMMISSION WASHINGTON, DC 20554
BEFORE THE FEDERAL COMMUNICATIONS COMMISSION WASHINGTON, DC 20554 In the Matter of ) ) Telecommunications Relay Services and ) CG Docket No. 03-123 Speech-to-Speech Services for Individuals ) With Hearing
More informationSTATEMENT OF THE AMERICAN DENTAL ASSOCIATION ON REGULATION BY STATE BOARDS OF DENTISTRY OF MISLEADING DENTAL SPECIALTY CLAIMS.
STATEMENT OF THE AMERICAN DENTAL ASSOCIATION ON REGULATION BY STATE BOARDS OF DENTISTRY OF MISLEADING DENTAL SPECIALTY CLAIMS August 10, 2018 From time to time, general dentists who are not adequately
More informationSUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated
This document is scheduled to be published in the Federal Register on 11/22/2017 and available online at https://federalregister.gov/d/2017-25245, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationAPPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS
APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 34 th EDITION THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT. U.S. DEPARTMENT
More informationPhilip Morris USA Inc. v. FDA
Philip Morris USA Inc. v. FDA STACY L. EHRLICH * AND JAMES WILLIAM WOODLEE ** WHY IT MADE THE LIST Philip Morris v. FDA 1 represents the latest in a string of (generally successful) industry challenges
More informationeffect that the Family Smoking Prevention and Tobacco Control Act ( FSPTCA ), which was
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA SMOKING EVERYWHERE, INC., Plaintiff, and Civ. No. 09-cv-0771 (RJL SOTTERA, INC., d/b/a NJOY, Intervenor-Plaintiff, v. U.S. FOOD AND DRUG ADMINISTRATION,
More informationOffice of Generic Drugs. April 14, 2010
Considerations for PET ANDAs Office of Generic Drugs April 14, 2010 1 Agenda Office of Generic Drugs: background information RLDs and Suitability Petitions Submission requirements for an ANDA Approval
More informationU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION Petition for Rulemaking on ) Functional Foods and ) Docket No. Request to Establish an ) Advisory Committee ) ) Submitted by the
More informationTOBACCO PRODUCT OR MEDICAL PRODUCT?
TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:
More informationCase 1:09-cv RMB-AMD Document 1 Filed 08/12/09 Page 1 of 6 PageID: 1
Case 1:09-cv-04115-RMB-AMD Document 1 Filed 08/12/09 Page 1 of 6 PageID: 1 John E. Flaherty Jonathan M.H. Short McCARTER & ENGLISH, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102-4096
More informationOctober 13, 2016 VIA ELECTRONIC SUBMISSION
Sandoz Inc. 100 College Road West Princeton, NJ 08540 USA Phone +1-609-627-8500 www.sandoz.com October 13, 2016 VIA ELECTRONIC SUBMISSION Division of Dockets Management (HFA-305) Food and Drug Administration
More informationBefore the FEDERAL COMMUNICATIONS COMMISSION Washington, DC PETITION FOR LIMITED WAIVER
Before the FEDERAL COMMUNICATIONS COMMISSION Washington, DC 20554 Misuse of Internet Protocol (IP Captioned Telephone Service Telecommunications Relay Services and Speech-to-Speech Services for Individuals
More informationCase 2:15-cv SRC-CLW Document 9 Filed 02/04/16 Page 1 of 19 PageID: 246
Case 2:15-cv-08180-SRC-CLW Document 9 Filed 02/04/16 Page 1 of 19 PageID: 246 Elvin Esteves Charles H. Chevalier J. Brugh Lower GIBBONS P.C. One Gateway Center Newark, New Jersey 07102 Tel: (973) 596-4500
More informationSeptember 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 28, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. : Center for Devices and Radiological Health 510(k)
More informationDEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical
This document is scheduled to be published in the Federal Register on 08/05/2016 and available online at http://federalregister.gov/a/2016-18660, and on FDsys.gov DEPARTMENT OF VETERANS AFFAIRS 8320-01
More informationBefore the OFFICE OF MANAGEMENT AND BUDGET Washington, D.C.
Before the OFFICE OF MANAGEMENT AND BUDGET Washington, D.C. In the Matter of ) ) ) Notice of Information Collection Being ) OMB Control No. 3060-0761 Submitted to the Office of Management and ) Budget
More informationRe: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationACTION: Notification; declaratory order; extension of compliance date.
This document is scheduled to be published in the Federal Register on 05/21/2018 and available online at https://federalregister.gov/d/2018-10714, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationIN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION MEMORANDUM OPINION AND ORDER
Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al Doc. 251 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION ALLERGAN, INC., Plaintiff, v. TEVA PHARMACEUTICALS
More informationRe: National Bioengineered Food Disclosure Standard; Proposed Rule; Request for Comments, 83 Fed. Reg (May 4, 2018), Docket No.
VIA ELECTRONIC SUBMISSION July 3, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: National Bioengineered Food Disclosure Standard;
More informationGuidance for Industry
Guidance for Industry Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation DRAFT GUIDANCE This guidance document is being
More informationA. Concentrated Omega-3 Dietary Supplements Provide Recognized Health Benefits
DEANNA TANNER OKUN Tel: (202) 407-8615 okun@adduci.com VIA ELECTRONIC FILING AND OVERNIGHT MAIL The Honorable Lisa R. Barton Secretary to the Commission United States International Trade Commission 500
More informationApril 30, By Electronic Mail
April 30, 2018 By Electronic Mail Dr. Scott Gottlieb, Commissioner Office of the Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 CommissionerFDA@fda.hhs.gov
More informationCase 1:16-cv UNA Document 1 Filed 04/22/16 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00289-UNA Document 1 Filed 04/22/16 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NOVARTIS AG, NOVARTIS PHARMACEUTICALS CORPORATION, MITSUBISHI
More informationCompare Results. 153 Replacements 26 Insertions 344 Deletions. Total Changes. Styling and. Content. 0 Annotations. Old File: New File:
3/1/2019 4:12:31 PM Compare Results Old File: Draft Guidance.pdf 20 pages (438 KB) 3/21/2018 3:55:17 PM versus New File: Final Guidance.pdf 21 pages (323 KB) 2/28/2019 11:42:05 AM Total Changes 523 Text
More informationORANGE BOOK ORANGE BOOK
1 INTRODUCTION: DEFINITION: The official title of the book is Approved Drug Products with Therapeutic Equivalence Evaluations. Orange book is a publication by the Food and Drug Administration which contains
More informationFood Labeling: Revision of the Nutrition and Supplement Facts Labels and Serving Sizes of
This document is scheduled to be published in the Federal Register on 10/02/2017 and available online at https://federalregister.gov/d/2017-21019, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationNDI: LOOKING BACK & AHEAD
NDI: LOOKING BACK & AHEAD Chi Hee Kim D i r e c t o r, W o r l d w i d e R e g u l a t o r y, G o v e r n m e n t a n d I n d u s t r y A f f a i r s H e r b a l i f e I n t e r n a t i o n a l o f A m
More informationHighly Concentrated Caffeine in Dietary Supplements; Guidance for Industry; Availability
This document is scheduled to be published in the Federal Register on 04/16/2018 and available online at https://federalregister.gov/d/2018-07836, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationMay 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org May 16, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationOverview of Regulatory Science of Food Contact Substances
Overview of Regulatory Science of Food Contact Substances Michael A. Adams, PhD Deputy Director, Office of Food Additive Safety FDA, Center for Food Safety and Applied Nutrition 5001 Campus Drive, College
More informationSoma)con PHARMACEUTICALS
Soma)con PHARMACEUTICALS 5357 11 OCT 20 A10 AO Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852
More informationAmyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationCase 1:17-cv UNA Document 1 Filed 02/14/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-00159-UNA Document 1 Filed 02/14/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PF PRISM C.V., and C.P. PHARMACEUTICALS INTERNATIONAL
More informationmemorandum Venable s FDA Practice Group FDA Publishes Draft Guidance on New Dietary Ingredients ( NDIs )
memorandum TO Valued Dietary Supplement Clients DATE July 5, 2011 FROM Venable s FDA Practice Group RE FDA Publishes Draft Guidance on New Dietary Ingredients ( NDIs ) On July 1, 2011, the U.S. Food and
More informationPolicy / Drug and Alcohol-Free Workshops
Policy 4118.235/4218.235 Drug and Alcohol-Free Workshops DATE: February 13, 2017 PREVIOUS ITEM: None ENCLOSURES: CABE s Suggested Policy 4118.235/4218.235 CABE s July 15, 2016 Policy Update REASON: To
More informationApril 13, In short, the Protocol is, at its core, flawed beyond repair for many reasons including, without limitation, the following:
Lewis Ressler Foods Unit, Policy, Standards, and Quality Assurance Section Consumer Protection Division P.O. Box 149347 Mail Code 1987 Austin, TX 78714-9347 Email: foods.regulatory@dshs.texas.gov Via US
More informationMini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801
Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801 Jarilyn Dupont, JD Director of Regulatory Policy, Office of Policy Office of Commissioner, U.S. Food
More informationPreparing a US FDA Medical Device 510(K) Submission
Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via
More informationUsing new scientific knowledge to update regulations in the U.S.
Using new scientific knowledge to update regulations in the U.S. Maricel Maffini, Ph.D. Food Packaging Forum 5 October, 2017 US Food Additives Regulatory Program Administered by the Food and Drug Administration
More informationGuidance for Industry
Guidance for Industry Dosage Delivery Devices for OTC Liquid Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationReference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,
tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby
More informationPaper Date: November 19, 2013 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
Trials@uspto.gov Paper 12 571-272-7822 Date: November 19, 2013 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD CARDIOCOM, LLC Petitioner v. UNIVERSITY OF ROCHESTER Patent
More informationOctober 25, Division of Dockets Management HFA-305 Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
October 25, 2011 Division of Dockets Management HFA-305 Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket Nos. FDA-2000-P-0102; FDA-2000-p-0133; and FDA-2006-P-0033:
More informationResponsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA.
Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA (Laser Notice 51) Document issued on: May 27, 2001 U.S. Department of Health
More informationINRANGE SYSTEMS. Citizen Petition
INRANGE SYSTEMS I~ I~ ;111Q I~ I tim@ II lifi11 Ill~ 1!1 II: I@ ;I@~ lij December 26, 2014 ZOI5 JA. -5 P 1: 15 Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Room 1061 (HFA-305)
More informationOctober 31, Draft Guidance for Industry, Frequently Asked Questions About Medical Foods; Second Edition
October 31, 2013 VIA ELECTRONIC SUBMISSION Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Rockville, MD 20852 Re: Docket No. FDA-2013-D-0880 Draft Guidance for
More informationDraft Guidance for Industry: ) Evidence-Based Review System for the ) Docket No. 2007D-0125 Scientific Evaluation of Health Claims )
Food and Drug Administration Division of Dockets Management (HFM-305) Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 Draft Guidance for Industry: ) Evidence-Based
More informationIndirect Food Additives: Adhesives and Components of Coatings and Paper and Paperboard Components
4 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 175 and 176 [Docket No. 99F-09253 Indirect Food Additives: Adhesives and Components of Coatings and Paper and Paperboard
More informationPlant Based Milk Labeling
NatAgLaw@uark.edu (479) 575-7646 www.nationalaglawcenter.org An Agricultural Law Research Publication Plant Based Milk Labeling by Cash Barker Research Fellow, National Agricultural Law Center & Rusty
More informationThe proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.
ADVISORY Food & Drug FDA ISSUES PROPOSED RULE TO ESTABLISH A UNIQUE DEVICE IDENTIFICATION SYSTEM FOR MEDICAL DEVICES July 16, 2012 On July 11, 2012, the Food and Drug Administration (FDA) published in
More informationANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum
ANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum Sarah Park, PharmD Jeanne Skanchy, RPh. Labeling Reviewers Office of Generic Drugs/Division of Labeling
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationPublic Hearing Before U.S. Food and Drug Administration
Substances in Food and Labeling; Regulatory Framework for Foods that Companies are Marketing as Functional Foods Public Hearing Before U.S. Food and Drug Administration Ilene Ringel Heller Senior Staff
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationPremarket Review. FFDCA Section 201(s) FFDCA Section 201(s) (cont.)
FFDCA Section 201(s) intended use of which results or may reasonably be expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food Mitchell
More informationIn the Matter of Portland General Electric Company 2016 Integrated Resource Plan Docket LC 66
Troutman Sanders LLP 100 SW Main St., Suite 1000 Portland, Oregon 97204 troutman.com Chris D. Zentz chris.zentz@troutman.com December 1, 2017 VIA ELECTRONIC FILING Oregon Public Utility Commission Attention:
More informationCHILD AND ADULT CARE FOOD PROGRAM ADMINISTRATIVE REVIEW PROCEDURES
CHILD AND ADULT CARE FOOD PROGRAM ADMINISTRATIVE REVIEW PROCEDURES The regulations and guidelines of the Child and Adult Care Food Program (CACFP or Program) under the Food and Nutrition Service (FNS)
More informationDEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) is amending its medical
This document is scheduled to be published in the Federal Register on 03/23/2017 and available online at https://federalregister.gov/d/2017-05799, and on FDsys.gov DEPARTMENT OF VETERANS AFFAIRS 8320-01
More informationSENATE, No. 359 STATE OF NEW JERSEY. 217th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2016 SESSION
SENATE, No. STATE OF NEW JERSEY th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 0 SESSION Sponsored by: Senator RICHARD J. CODEY District (Essex and Morris) Senator JOSEPH F. VITALE District (Middlesex)
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationSUMMARY: The Food and Drug Administration (FDA or we) is amending the color additive
This document is scheduled to be published in the Federal Register on 08/21/2015 and available online at http://federalregister.gov/a/2015-20676, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More information